Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia

Hua Jay J. Cherng; Nitin Jain; Beenu Thakral; Tariq Muzzafar; Roberto N. Miranda; Dongfeng Tan; Asif Rashid; Neda Kalhor; Andrew W. Hahn; Lauren A. Byers; Christine M. Parseghian; Alessandra Ferrajoli; Naveen Pemmaraju

doi:10.1016/j.leukres.2020.106445

Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia

Hua Jay J. Cherng, Nitin Jain, Beenu Thakral, Tariq Muzzafar, Roberto N. Miranda, Dongfeng Tan, Asif Rashid, Neda Kalhor, Andrew W. Hahn, Lauren A. Byers, Christine M. Parseghian, Alessandra Ferrajoli, Naveen Pemmaraju

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English (US)
Article number	106445
Journal	Leukemia Research
Volume	98
DOIs	https://doi.org/10.1016/j.leukres.2020.106445
State	Published - Nov 2020

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1016/j.leukres.2020.106445

Cite this

Cherng, H. J. J., Jain, N., Thakral, B., Muzzafar, T., Miranda, R. N., Tan, D., Rashid, A., Kalhor, N., Hahn, A. W., Byers, L. A., Parseghian, C. M., Ferrajoli, A., & Pemmaraju, N. (2020). Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leukemia Research, 98, Article 106445. https://doi.org/10.1016/j.leukres.2020.106445

@article{717e6694763641558f4e508a787e3db1,

title = "Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia",

author = "Cherng, {Hua Jay J.} and Nitin Jain and Beenu Thakral and Tariq Muzzafar and Miranda, {Roberto N.} and Dongfeng Tan and Asif Rashid and Neda Kalhor and Hahn, {Andrew W.} and Byers, {Lauren A.} and Parseghian, {Christine M.} and Alessandra Ferrajoli and Naveen Pemmaraju",

note = "Funding Information: This research is supported in part by the M. D. Anderson Cancer Center Support Grant P30 CA016672 and the SagerStrong Foundation . Authors not listed have no disclosures to report. NJ : Research funding : AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Aprea Therapeutics. Advisory board/honoraria : Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies, Servier, Precision Biosciences, TG Therapeutics, Beigene. LB : Advisor/consultant and research funding : AstraZeneca, GenMab, Sierra Oncology. Research funding : ToleroPharmaceuticals. Advisor/consultant only : PharmaMar, AbbVie, Bristol-Myers Squibb, Alethia, Merck, Pfizer, Jazz Pharmaceuticals. NP : Consulting/honorarium : Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Diagnostics, LFB, Pacylex, AbbVie; Research funding/clinical trials support : Stemline; Novartis; AbbVie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix, SagerStrong Foundation. Funding Information: This research is supported in part by the M. D. Anderson Cancer Center Support Grant P30 CA016672 and the SagerStrong Foundation. Authors not listed have no disclosures to report. NJ: Research funding: AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Aprea Therapeutics. Advisory board/honoraria: Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies, Servier, Precision Biosciences, TG Therapeutics, Beigene. LB: Advisor/consultant and research funding: AstraZeneca, GenMab, Sierra Oncology. Research funding: ToleroPharmaceuticals. Advisor/consultant only: PharmaMar, AbbVie, Bristol-Myers Squibb, Alethia, Merck, Pfizer, Jazz Pharmaceuticals. NP: Consulting/honorarium: Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Diagnostics, LFB, Pacylex, AbbVie; Research funding/clinical trials support: Stemline; Novartis; AbbVie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix, SagerStrong Foundation.",

year = "2020",

month = nov,

doi = "10.1016/j.leukres.2020.106445",

language = "English (US)",

volume = "98",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia

AU - Cherng, Hua Jay J.

AU - Jain, Nitin

AU - Thakral, Beenu

AU - Muzzafar, Tariq

AU - Miranda, Roberto N.

AU - Tan, Dongfeng

AU - Rashid, Asif

AU - Kalhor, Neda

AU - Hahn, Andrew W.

AU - Byers, Lauren A.

AU - Parseghian, Christine M.

AU - Ferrajoli, Alessandra

AU - Pemmaraju, Naveen

N1 - Funding Information: This research is supported in part by the M. D. Anderson Cancer Center Support Grant P30 CA016672 and the SagerStrong Foundation . Authors not listed have no disclosures to report. NJ : Research funding : AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Aprea Therapeutics. Advisory board/honoraria : Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies, Servier, Precision Biosciences, TG Therapeutics, Beigene. LB : Advisor/consultant and research funding : AstraZeneca, GenMab, Sierra Oncology. Research funding : ToleroPharmaceuticals. Advisor/consultant only : PharmaMar, AbbVie, Bristol-Myers Squibb, Alethia, Merck, Pfizer, Jazz Pharmaceuticals. NP : Consulting/honorarium : Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Diagnostics, LFB, Pacylex, AbbVie; Research funding/clinical trials support : Stemline; Novartis; AbbVie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix, SagerStrong Foundation. Funding Information: This research is supported in part by the M. D. Anderson Cancer Center Support Grant P30 CA016672 and the SagerStrong Foundation. Authors not listed have no disclosures to report. NJ: Research funding: AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, Precision Biosciences, Fate Therapeutics, Aprea Therapeutics. Advisory board/honoraria: Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies, Servier, Precision Biosciences, TG Therapeutics, Beigene. LB: Advisor/consultant and research funding: AstraZeneca, GenMab, Sierra Oncology. Research funding: ToleroPharmaceuticals. Advisor/consultant only: PharmaMar, AbbVie, Bristol-Myers Squibb, Alethia, Merck, Pfizer, Jazz Pharmaceuticals. NP: Consulting/honorarium: Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Diagnostics, LFB, Pacylex, AbbVie; Research funding/clinical trials support: Stemline; Novartis; AbbVie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix, SagerStrong Foundation.

PY - 2020/11

Y1 - 2020/11

UR - http://www.scopus.com/inward/record.url?scp=85090726793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090726793&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2020.106445

DO - 10.1016/j.leukres.2020.106445

M3 - Letter

C2 - 32937250

AN - SCOPUS:85090726793

SN - 0145-2126

VL - 98

JO - Leukemia Research

JF - Leukemia Research

M1 - 106445

ER -

Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this